New Drug ‘Functionally Cures’ Many Hepatitis B Virus Infections

Why It Matters

A functional cure could slash lifelong treatment costs and reduce the 1.1 million annual HBV deaths, reshaping the global hepatitis B market. However, limited applicability to the broader infected pool tempers its immediate public‑health impact.

Key Takeaways

• Bepi achieved 19% functional cure in phase 3 HBV trials.
• Cure rate rose to 26% for patients with lowest surface antigen.
• Drug works as antisense oligonucleotide, targeting HBV mRNA.
• Only 5% of diagnosed HBV patients currently receive treatment.
• Regulatory filings submitted globally; approvals expected later this year.

Pulse Analysis

Hepatitis B remains a silent pandemic, with roughly 240 million chronic carriers and over a million deaths each year. Existing nucleos(t)ide analogues suppress viral replication but require indefinite dosing, and fewer than one percent achieve off‑therapy control. The disease’s persistence stems from covalently closed circular DNA that integrates into host cells, making eradication elusive. In this landscape, a functional cure—sustained loss of viral DNA and surface antigen—represents a pragmatic target that could dramatically lower treatment burdens and healthcare expenditures.

GSK’s bepirovirsen, an antisense oligonucleotide, binds HBV messenger RNA, halting protein production and flagging infected cells for immune clearance. In the recent phase 3 program, 233 of 1,220 participants receiving bepi plus standard therapy achieved functional cure, compared with none in the placebo arm. Notably, the effect amplified to 26% among patients entering with the lowest hepatitis B surface antigen, suggesting that baseline viral load is a key predictor of success. Side effects were frequent but rarely severe, and durability beyond six months remains under observation, though phase 2 data hint at multi‑year suppression.

Regulatory submissions are now underway in major markets, and GSK signals intent to price the therapy in line with both innovation value and patient access. If approved, bepirovirsen could open a new revenue stream for the company while prompting insurers to reassess long‑term antiviral budgets. Nonetheless, experts caution that the drug’s efficacy in untreated, high‑antigen, or cirrhotic cohorts is unproven, underscoring the need for combination strategies and broader industry collaboration. Continued real‑world data will determine whether functional cures become a standard endpoint in hepatitis B management.